Regulators are examining whether there is a link between Type 2 diabetes drug Actos and bladder cancer, according to an article from WebMD.
Early data suggests there may be one, but not enough of a link to cause the FDA to pull the drug from the market. When the regulator initially approved the drug, it required Takeda Pharmaceuticals to keep data on a possible link.
The article suggests that no increased risk was found simply (more…)
The U.S. Food and Drug Administration announced it has begun a safety review of the diabetes drug Actos (pioglitazone), after receiving preliminary results from a long-term observational study designed to evaluate the risk of bladder cancer associated with use of this drug.
The preliminary results are based on five-year data from an ongoing, 10-year observational study by the manufacturer, Takeda Pharmaceuticals North (more…)
The U.S. Food and Drug Administration (FDA) announced on Sept. 17 that it has begun a safety review of the diabetes drug pioglitazone (Actos) in response to early results from a long–term study to evaluate the risk of bladder cancer associated with this drug.
The preliminary results are based on five–year data from an ongoing‚ 10–year observational study by drugmaker Takeda Pharmaceuticals North America Inc. The early findings showed (more…)
Newly published research shows Avandia poses roughly the same heart-attack risk as competing drug Actos, contradicting earlier studies suggesting Avandia was more dangerous.
The new study, published this week in the journal Circulation: Cardiovascular Quality and Outcomes, may have arrived at a different conclusion in part because its subjects may have been younger and healthier than in previous studies, says study author Debra (more…)
A new analysis of diabetes medications Avandia (rosiglitazone) and Actos (pioglitazone) revealed that the risk of heart attack and/or heart failure, or death were the same, approximately 4%. The study has been published in the latest issue of Circulation: Cardiovascular Quality and Outcomes , an American Heart Association journal.
Takeda Pharmacuetical Co. makes Actos, while GlaxoSmithKline (GSK) makes Avandia. (more…)